T. Rowe Price Associates’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$741K Buy
78,581
+15,506
+25% +$170K ﹤0.01% 2279
2025
Q4
$784K Buy
63,075
+2,618
+4% +$34.8K ﹤0.01% 2187
2025
Q3
$867K Buy
60,457
+4,066
+7% +$55.7K ﹤0.01% 2129
2025
Q2
$692K Buy
56,391
+4,745
+9% +$68.9K ﹤0.01% 2148
2025
Q1
$1.14M Buy
51,646
+4,556
+10% +$107K ﹤0.01% 1890
2024
Q4
$1.07M Buy
47,090
+4,452
+10% +$97.2K ﹤0.01% 1938
2024
Q3
$775K Buy
42,638
+614
+1% +$14.2K ﹤0.01% 2071
2024
Q2
$1.23M Buy
42,024
+6,603
+19% +$196K ﹤0.01% 1809
2024
Q1
$1.26M Buy
35,421
+2,114
+6% +$84.5K ﹤0.01% 1804
2023
Q4
$1.45M Buy
33,307
+1,929
+6% +$75.9K ﹤0.01% 1692
2023
Q3
$1.2M Buy
31,378
+910
+3% +$38.3K ﹤0.01% 1713
2023
Q2
$1.25M Sell
30,468
-2,908
-9% -$140K ﹤0.01% 1688
2023
Q1
$1.92M Buy
33,376
+1,172
+4% +$66K ﹤0.01% 1473
2022
Q4
$1.81M Sell
32,204
-3,381
-10% -$172K ﹤0.01% 1509
2022
Q3
$1.51M Buy
35,585
+5,373
+18% +$275K ﹤0.01% 1559
2022
Q2
$1.63M Buy
30,212
+149
+0.5% +$8.95K ﹤0.01% 1689
2022
Q1
$1.93M Buy
30,063
+1,712
+6% +$113K ﹤0.01% 1695
2021
Q4
$1.9M Sell
28,351
-1,887
-6% -$128K ﹤0.01% 1738
2021
Q3
$2.07M Buy
30,238
+1,551
+5% +$110K ﹤0.01% 1710
2021
Q2
$1.96M Sell
28,687
-140
-0.5% -$9.9K ﹤0.01% 1741
2021
Q1
$1.99M Sell
28,827
-1,663
-5% -$113K ﹤0.01% 1724
2020
Q4
$1.98M Buy
30,490
+614
+2% +$33K ﹤0.01% 1640
2020
Q3
$1.41M Sell
29,876
-4,980
-14% -$237K ﹤0.01% 1661
2020
Q2
$1.64M Buy
34,856
+4,711
+16% +$232K ﹤0.01% 1593
2020
Q1
$1.35M Buy
30,145
+1,164
+4% +$61.1K ﹤0.01% 1609
2019
Q4
$1.69M Buy
28,981
+2,143
+8% +$128K ﹤0.01% 1669
2019
Q3
$1.61M Buy
26,838
+237
+0.9% +$14.1K ﹤0.01% 1634
2019
Q2
$1.49M Buy
26,601
+24
+0.1% +$1.24K ﹤0.01% 1686
2019
Q1
$1.48M Buy
26,577
+130
+0.5% +$6.62K ﹤0.01% 1693
2018
Q4
$1.19M Buy
26,447
+89
+0.3% +$4.88K ﹤0.01% 1733
2018
Q3
$1.74M Sell
26,358
-1
-0% -$62 ﹤0.01% 1667
2018
Q2
$1.7M Buy
26,359
+74
+0.3% +$4.58K ﹤0.01% 1638
2018
Q1
$1.46M Buy
26,285
+124
+0.5% +$6.5K ﹤0.01% 1651
2017
Q4
$1.25M Buy
26,161
+1,690
+7% +$82.7K ﹤0.01% 1711
2017
Q3
$1.24M Hold
24,471
﹤0.01% 1721
2017
Q2
$1.33M Buy
24,471
+5
+0% +$239 ﹤0.01% 1675
2017
Q1
$1.03M Buy
24,466
+5,300
+28% +$226K ﹤0.01% 1784
2016
Q4
$822K Buy
19,166
+6
+0% +$244 ﹤0.01% 1849
2016
Q3
$791K Sell
19,160
-800
-4% -$33.5K ﹤0.01% 1835
2016
Q2
$796K Sell
19,960
-6,180
-24% -$222K ﹤0.01% 1777
2016
Q1
$880K Buy
26,140
+6,000
+30% +$187K ﹤0.01% 1751
2015
Q4
$683K Sell
20,140
-5,660
-22% -$177K ﹤0.01% 1822
2015
Q3
$768K Sell
25,800
-5,759
-18% -$180K ﹤0.01% 1787
2015
Q2
$869K Buy
31,559
+8,318
+36% +$222K ﹤0.01% 1802
2015
Q1
$586K Sell
23,241
-734
-3% -$17.4K ﹤0.01% 1919
2014
Q4
$531K Hold
23,975
﹤0.01% 1944
2014
Q3
$486K Hold
23,975
﹤0.01% 1946
2014
Q2
$461K Buy
23,975
+4,893
+26% +$91.2K ﹤0.01% 1989
2014
Q1
$359K Sell
19,082
-5,138
-21% -$99.2K ﹤0.01% 2072
2013
Q4
$472K Sell
24,220
-118,654
-83% -$2.18M ﹤0.01% 1934
2013
Q3
$2.35M Buy
142,874
+734
+0.5% +$11.8K ﹤0.01% 1525
2013
Q2
$2.13M Buy
+142,140
New +$2.08M ﹤0.01% 1518

Other funds holding IART

T. Rowe Price Associates's IART Position: Q1 2026 in Review

T. Rowe Price Associates increased its Integra LifeSciences (IART) stake by 25% in Q1 2026, buying an estimated $170K and bringing the position to 78,581 shares worth $741K. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

T. Rowe Price Associates first reported a position in IART in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.35M in Q3 2013. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • T. Rowe Price Associates held 78,581 shares of Integra LifeSciences worth $741K as of Q1 2026.
  • T. Rowe Price Associates bought 15,506 Integra LifeSciences shares in Q1 2026, an estimated $170K.
  • Integra LifeSciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2279 holding.
  • T. Rowe Price Associates first reported a position in Integra LifeSciences in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Integra LifeSciences position peaked at $2.35M in Q3 2013.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.